CorMedix Inc. (NASDAQ:CRMD) Q3 2023 Earnings Call Transcript

Joseph Todisco: Sure. Thanks, Dan. So right, as we mentioned, we’re expecting a soft launch in the early part of the year that we would look to certainly accelerate as we get our outpatient reimbursement solidified, whether it’s TDAPA or a separate payment. We would expect to give some directional revenue guidance, hopefully, on our next earnings call, should — provided we have a reimbursement determination from CMS. But along the way, I think there’s going to be catalysts that certainly we can talk about and report, whether it’s certain health systems formulary status, potentially agreements with LDOs or MDOs, right, that where we could point to, directional revenue guidance and value. And all of that could certainly be over the upcoming months.

Daniel Ferry: Excellent. Thanks Joe. One final one here. It’s a good segue. What do you view as some of the key catalysts going into 2024 for CorMedix?

Joseph Todisco: Yes. So obviously, I touched on some of them. The first and foremost is approval. We have to lock down NDA approval, hopefully, tomorrow. Beyond that, we’re waiting on a decision from CMS around the reimbursement structure for DefenCath. That will guide how we roll out our launch strategy and inpatient and outpatient. But some of those key catalysts that I just mentioned, potential agreements with LDOs or MDOs, updates around larger health systems, P&T and formulary adoption. And potentially, later next year, updating on label expansion for DefenCath into additional indications.

Daniel Ferry: Excellent. Thank you, Joe. Operator, you may now close the call.

Operator: Thank you, presenters. And ladies and gentlemen, this concludes today’s conference call. Thank you for participating. You may now disconnect.